A randomized, multicenter, open-label, phase 2b study of VELCADE [bortezomib] alone and VELCADE plus irinotecan in patients with relapsed or refractory colorectal carcinoma
Phase of Trial: Phase II
Latest Information Update: 22 Jul 2008
At a glance
- Drugs Bortezomib; Irinotecan
- Indications Colorectal cancer
- Focus Therapeutic Use
- 22 Jul 2008 Results have been published.
- 13 Feb 2008 The expected completion date for this trial is now 1 Mar 2004.
- 08 Feb 2008 Status changed from in progress to completed.